Dr. Michael Rickels, MD, MS
Claim this profileUniversity of Pennsylvania - Institute for Diabetes, Obesity and Metabolism
Studies Cystic Fibrosis
Studies Diabetes Mellitus
5 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Michael Rickels, MD, MS is currently running
GLP-1 Agonist Therapy
for Cystic Fibrosis-related Diabetes
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions to preserve β-cell function are crucial for delaying and potentially preventing CFRD development. In this study, we hypothesize that weekly administration of the long-acting glucagon-like peptide-1 (GLP-1) agonist dulaglutide will improve defective early-phase insulin secretion and improve glucose tolerance during a mixed-meal tolerance test.
Recruiting1 award Phase 2
Incretin Hormones
for Cystic Fibrosis
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has many features similar to both T1D and T2D, patients with CF may not have the same symptoms as either T1D or T2D patients. Currently, there is little understanding of CFRD and the best options for treatment remain unclear. The purpose of this research study is to examine and understand the various mechanisms that contribute to CFRD and gain a better understanding of potential means to treat CFRD. In particular, we plan to study the effects of incretin hormones that can enhance insulin production in CF patients. Enrollment is complete for the protocol as initially written. In order to further study the role of the incretin hormone on Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function , we have received approval to extend our investigation to include the following study groups: * Cystic Fibrosis participants with normal glucose tolerance * Non-Cystic Fibrosis controls
Recruiting1 award N/A5 criteria
More about Michael Rickels, MD, MS
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Michael Rickels, MD, MS has experience with
- Dulaglutide
- GIP
- GLP-1
- MiniMed 670G System
- RT-CGM
- Standard Therapy Plus Continuous Glucose Monitoring (CGM)
Breakdown of trials Michael Rickels, MD, MS has run
Cystic Fibrosis
Diabetes Mellitus
Pancreatic Insufficiency
Hypoglycemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Rickels, MD, MS specialize in?
Michael Rickels, MD, MS focuses on Cystic Fibrosis and Diabetes Mellitus. In particular, much of their work with Cystic Fibrosis has involved CFTR positive patients, or patients who are undergoing treatment.
Is Michael Rickels, MD, MS currently recruiting for clinical trials?
Yes, Michael Rickels, MD, MS is currently recruiting for 2 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Michael Rickels, MD, MS has studied deeply?
Yes, Michael Rickels, MD, MS has studied treatments such as Dulaglutide, GIP, GLP-1.
What is the best way to schedule an appointment with Michael Rickels, MD, MS?
Apply for one of the trials that Michael Rickels, MD, MS is conducting.
What is the office address of Michael Rickels, MD, MS?
The office of Michael Rickels, MD, MS is located at: University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism, Philadelphia, Pennsylvania 19104 United States. This is the address for their practice at the University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.